Troxonium tosylate in the treatment of drug-induced extrapyramidal manifestations.
D000328:Adult; D001565:Benzoates / Q000627:therapeutic use*; D002794:Choline / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004952:Esters / Q000627:therapeutic use; D000431:Ethanol; D005116:Extrapyramidal Tracts / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000008:administration & dosage / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000188:drug therapy; D000644:Quaternary Ammonium Compounds / Q000627:therapeutic use*; D013451:Sulfonic Acids / Q000627:therapeutic use
D001565:Benzoates; D004952:Esters; D010276:Parasympatholytics; D000644:Quaternary Ammonium Compounds; D013451:Sulfonic Acids; D000431:Ethanol; D002794:Choline